pCas2A Citations (2)

Originally described in: CRISPR interference as a titratable, trans-acting regulatory tool for metabolic engineering in the cyanobacterium Synechococcus sp. strain PCC 7002.
Gordon GC, Korosh TC, Cameron JC, Markley AL, Begemann MB, Pfleger BF Metab Eng. 2016 Jul 29. pii: S1096-7176(16)30062-3. doi: 10.1016/j.ymben.2016.07.007. PubMed Journal

---

Articles Citing pCas2A

Articles
Computational inference of cancer-specific vulnerabilities in clinical samples. Jang K, Park MJ, Park JS, Hwangbo H, Sung MK, Kim S, Jung J, Lee JW, Ahn SH, Chang S, Choi JK. Genome Biol. 2020 Jun 29;21(1):155. doi: 10.1186/s13059-020-02077-1. PubMed
Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis. Choi YS, Kim MJ, Choi EA, Kim S, Lee EJ, Park MJ, Kim MJ, Kim YW, Ahn HS, Jung JY, Jang G, Kim Y, Kim H, Kim K, Kim JY, Hong SM, Kim SC, Chang S. Proc Natl Acad Sci U S A. 2022 Jul 26;119(30):e2119048119. doi: 10.1073/pnas.2119048119. Epub 2022 Jul 18. PubMed

If you have published an article using this material, please email us at to have your article added to this page.